{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:04:32Z","timestamp":1758672272320,"version":"3.44.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,22]]},"DOI":"10.7759\/cureus.92968","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T01:03:43Z","timestamp":1758589423000},"source":"Crossref","is-referenced-by-count":0,"title":["Valbenazine for the Treatment of Chronic Motor or Vocal Tic Disorder (CMVTD)"],"prefix":"10.7759","author":[{"given":"Adam","family":"Bied","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anant Akash","family":"Sakthivel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ritvij","family":"Satodiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20050","article-title":"The DSM-5: classification and criteria changes","volume":"12","author":"Regier DA","year":"2013","unstructured":"Regier DA, Kuhl EA, Kupfer DJ. The DSM-5: classification and criteria changes. World Psychiatry. 2013, 12:92-8. 10.1002\/wps.20050","journal-title":"World Psychiatry"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1517\/14728214.10.2.365","article-title":"Emerging drugs in Tourette syndrome","volume":"10","author":"Silay YS","year":"2005","unstructured":"Silay YS, Jankovic J. Emerging drugs in Tourette syndrome. Expert Opin Emerg Drugs. 2005, 10:365-80. 10.1517\/14728214.10.2.365","journal-title":"Expert Opin Emerg Drugs"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2013.09.015","article-title":"Practice parameter for the assessment and treatment of children and adolescents with tic disorders","volume":"52","author":"Murphy TK","year":"2013","unstructured":"Murphy TK, Lewin AB, Storch EA, Stock S. Practice parameter for the assessment and treatment of children and adolescents with tic disorders. J Am Acad Child Adolesc Psychiatry. 2013, 52:1341-59. 10.1016\/j.jaac.2013.09.015","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.781946","article-title":"Dopamine receptor partial agonists: do they differ in their clinical efficacy?","volume":"12","author":"Mohr P","year":"2021","unstructured":"Mohr P, Masopust J, Kope\u010dek M. Dopamine receptor partial agonists: do they differ in their clinical efficacy?. Front Psychiatry. 2021, 12:781946. 10.3389\/fpsyt.2021.781946","journal-title":"Front Psychiatry"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2015.1029573","article-title":"Valbenazine granted breakthrough drug status for treating tardive dyskinesia","volume":"24","author":"M\u00fcller T","year":"2015","unstructured":"M\u00fcller T. Valbenazine granted breakthrough drug status for treating tardive dyskinesia. Expert Opin Investig Drugs. 2015, 24:737-42. 10.1517\/13543784.2015.1029573","journal-title":"Expert Opin Investig Drugs"},{"key":"ref6","article-title":"Valbenazine (Ingrezza): the first FDA-approved treatment for tardive dyskinesia","volume":"43","author":"Uhlyar S","year":"2018","unstructured":"Uhlyar S, Rey JA. Valbenazine (Ingrezza): the first FDA-approved treatment for tardive dyskinesia. Pharmacy and Therapeutics. 2018, 43:328-31.","journal-title":"Pharmacy and Therapeutics"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00127-8","article-title":"Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington\u2019s disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"22","author":"Stimming E","year":"2023","unstructured":"Stimming E, Claassen DO, Kayson E, et al.. Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington\u2019s disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2023, 22:494-504. 10.1016\/S1474-4422(23)00127-8","journal-title":"Lancet Neurol"},{"key":"ref8","article-title":"Valbenazine therapy and CYP2D6 genotype","author":"Kane M","year":"2024","unstructured":"Kane M. Valbenazine therapy and CYP2D6 genotype. Medical Genetics Summaries. Pratt VM, Scott SA, Pirmohamed M, et al. (ed): National Center for Biotechnology Information (US), Bethesda, MD; 2024."},{"key":"ref9","article-title":"Valbenazine and deutetrabenazine for tardive dyskinesia","volume":"15","author":"Touma KT","year":"2018","unstructured":"Touma KT, Scarff JR. Valbenazine and deutetrabenazine for tardive dyskinesia. Innov Clin Neurosci. 2018, 15:13-6.","journal-title":"Innov Clin Neurosci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55361-0","article-title":"Drug inhibition and substrate transport mechanisms of human VMAT2","volume":"16","author":"Wei F","year":"2025","unstructured":"Wei F, Liu H, Zhang W, Wang J, Zhang Y. Drug inhibition and substrate transport mechanisms of human VMAT2. Nat Commun. 2025, 16:323. 10.1038\/s41467-024-55361-0","journal-title":"Nat Commun"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/s41537-025-00618-w","article-title":"Unique and overlapping mechanisms of valbenazine, deutetrabenazine, and vitamin E for tardive dyskinesia","volume":"11","author":"Li C","year":"2025","unstructured":"Li C, Zhuo C, Ma X, et al.. Unique and overlapping mechanisms of valbenazine, deutetrabenazine, and vitamin E for tardive dyskinesia. Schizophrenia (Heidelb). 2025, 11:69. 10.1038\/s41537-025-00618-w","journal-title":"Schizophrenia (Heidelb)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2021.1898948","article-title":"Clinical development of valbenazine for tics associated with Tourette syndrome","volume":"21","author":"Farber RH","year":"2021","unstructured":"Farber RH, Angelov A, Kim K, Carmack T, Thai-Cuarto D, Roberts E. Clinical development of valbenazine for tics associated with Tourette syndrome. Expert Rev Neurother. 2021, 21:393-404. 10.1080\/14737175.2021.1898948","journal-title":"Expert Rev Neurother"},{"key":"ref13","unstructured":"National Library of Medicine. ClinicalTrials.gov - Search results for Valbenazine (recruiting studies). Accessed. August 12, 2025: https:\/\/clinicaltrials.gov\/search?term=valbenazine&cond=tic+disorder&recrs=abdf ."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28957","article-title":"Meta-analysis: efficacy and tolerability of vesicular monoamine transporter type 2 inhibitors in the treatment of tic disorders","volume":"37","author":"Behling E","year":"2022","unstructured":"Behling E, Farhat LC, Landeros-Weisenberger A, Bloch MH. Meta-analysis: efficacy and tolerability of vesicular monoamine transporter type 2 inhibitors in the treatment of tic disorders. Mov Disord. 2022, 37:684-93. 10.1002\/mds.28957","journal-title":"Mov Disord"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-198907000-00015","article-title":"The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity","volume":"28","author":"Leckman JF","year":"1989","unstructured":"Leckman JF, Riddle MA, Hardin MT, Ort SI, Swartz KL, Stevenson J, Cohen DJ. The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry. 1989, 28:566-73. 10.1097\/00004583-198907000-00015","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"ref16","unstructured":"ClinicalTrials.gov. Safety and efficacy of NBI-98854 in pediatric subjects with Tourette Syndrome (T-Force GREEN). (2022). Accessed. August 20, 2025: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03530293."},{"key":"ref17","article-title":"Tetrabenazine (Xenazine), an FDA-approved treatment option for Huntington\u2019s disease-related chorea","volume":"33","author":"Yero T","year":"2008","unstructured":"Yero T, Rey JA. Tetrabenazine (Xenazine), an FDA-approved treatment option for Huntington\u2019s disease-related chorea. Pharmacy and Therapeutics. 2008, 33:690-4.","journal-title":"Pharmacy and Therapeutics"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S133205","article-title":"Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Solmi M","year":"2018","unstructured":"Solmi M, Pigato G, Kane JM, Correll CU. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2018, 12:1215-38. 10.2147\/DDDT.S133205","journal-title":"Drug Des Devel Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/408672-valbenazine-for-the-treatment-of-chronic-motor-or-vocal-tic-disorder-cmvtd","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T01:03:45Z","timestamp":1758589425000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/408672-valbenazine-for-the-treatment-of-chronic-motor-or-vocal-tic-disorder-cmvtd"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,22]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.92968","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,22]]}}}